NCT05011396: A trial that was reported late by VistaGen Therapeutics, Inc.
This trial has reported, although it was 302 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT05011396 |
|---|---|
| Title | A US, Phase 3 Multicenter, Randomized, Double-blind, Placebo Controlled Trial of PH94B Nasal Spray for the Acute Treatment of Anxiety Induced by a Public Speaking Challenge in Adult Subjects With Social Anxiety Disorder (PaliSADe-2) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 30, 2021 |
| Completion date | Aug. 16, 2022 |
| Required reporting date | Aug. 16, 2023, midnight |
| Actual reporting date | June 13, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 302 |